HMNC Brain Health aims to address the significant unmet medical need of millions of patients who are not helped sufficiently by existing mental health therapies. We are fully committed to bringing precision to these psychiatric disorders, in parallel to developing our existing pipeline, through our active R&D program in precision tools and biomarkers.

Genetic tests in combination with treatment are already a common protocol in other medical areas, such as oncology, but are still a novelty in psychiatry.

HMNC Brain Health is researching and developing biomarkers and other precision tools, including patented genetic tests developed alongside with world-leading scientists from the Max Planck Institute. Our aim is to combine these with innovative medications, resulting in targeted and personalized therapies for Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).

As a result, patients could benefit from earlier onset of effect and higher remission rates, as well as reduced side effects.